Prof. Van Den Bosch obtained a PhD in Physiology at the KU Leuven, Belgium, in 1990. Van Den Bosch pursued his career with postdoctoral positions in molecular biology and neurodegeneration. In 1996, he co-established the Laboratory of Neurobiology and a few years later he became Assistant Professor at the KU Leuven. In 2013, he was promoted to Full Professor in the Neurosciences Department. Since 2014, Van Den Bosch has been a group leader at the VIB Center for Brain & Disease Research in Leuven, Belgium.

In 2017, he became director of the Laboratory of Neurology (Experimental Neurology). His research is focused on motor neuron diseases such as amyotrophic lateral sclerosis (ALS) and different neuropathies such as Charcot-Marie-Tooth disease (CMT). The aim of his research is to obtain a more in-depth understanding of the mechanisms of neuronal and axonal degeneration and regeneration, as well as translating these discoveries into new therapeutic strategies for these different neurodegenerative disorders. His founding scientific discoveries in CMT and ALS, published in Nature journals in 2011 and 2017 respectively, constitute the most advanced assets of Augustine Therapeutics.